CNS Pharmaceuticals (NASDAQ:CNSP) Trading Down 5.5%

CNS Pharmaceuticals, Inc. (NASDAQ:CNSPGet Rating)’s stock price was down 5.5% during trading on Monday . The company traded as low as $0.21 and last traded at $0.23. Approximately 329,537 shares were traded during mid-day trading, a decline of 67% from the average daily volume of 1,003,372 shares. The stock had previously closed at $0.24.

Analyst Upgrades and Downgrades

Separately, Maxim Group cut shares of CNS Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 17th.

CNS Pharmaceuticals Stock Down 5.5 %

The business’s 50-day moving average is $0.24 and its two-hundred day moving average is $0.29. The company has a market capitalization of $9.01 million, a P/E ratio of -0.56 and a beta of 1.33.

Institutional Trading of CNS Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of CNSP. Bank of New York Mellon Corp raised its position in shares of CNS Pharmaceuticals by 689.3% in the first quarter. Bank of New York Mellon Corp now owns 234,892 shares of the company’s stock valued at $80,000 after purchasing an additional 205,134 shares during the period. Renaissance Technologies LLC grew its stake in CNS Pharmaceuticals by 242.9% during the first quarter. Renaissance Technologies LLC now owns 506,532 shares of the company’s stock valued at $173,000 after acquiring an additional 358,832 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in CNS Pharmaceuticals during the first quarter valued at approximately $38,000. Institutional investors own 3.04% of the company’s stock.

CNS Pharmaceuticals Company Profile

(Get Rating)

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme.

Recommended Stories

Receive News & Ratings for CNS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CNS Pharmaceuticals and related companies with's FREE daily email newsletter.